Clinical Trial Details
| Trial ID: | L3326 |
| Source ID: | NCT01972724 |
| Associated Drug: | Pioglitazone |
| Title: | Efficacy of Pioglitazone in Participants With Inadequately Controlled Type 2 Diabetes Mellitus Treated With Stable Triple Oral Therapy |
| Acronym: | ADD |
| Status: | COMPLETED |
| Study Results: | YES |
| Results: | https://ClinicalTrials.gov/show/NCT01972724/results |
| Conditions: | Type II Diabetes Mellitus |
| Interventions: | DRUG: Pioglitazone|DRUG: Metformin|DRUG: Sulfonylurea |
| Outcome Measures: | Primary: Change From Baseline in Glycosylated Hemoglobin (HbA1c) at Week 24, The change from baseline in glycosylated hemoglobin (the concentration of glucose bound to hemoglobin as a percent of the absolute maximum that can be bound) at Week 24. A negative change from baseline indicates improvement., Baseline and Week 24 | Secondary: Change From Baseline in Fasting Plasma Glucose at Week 24, The change between the value of fasting serum glucose collected at Week 24 and fasting serum glucose collected at baseline. A negative change from baseline indicates improvement., Baseline and Week 24 |
| Sponsor/Collaborators: | Sponsor: Takeda |
| Gender: | ALL |
| Age: | ADULT, OLDER_ADULT |
| Phases: | PHASE4 |
| Enrollment: | 114 |
| Study Type: | INTERVENTIONAL |
| Study Designs: | Allocation: RANDOMIZED|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT |
| Start Date: | 2013-12-16 |
| Completion Date: | 2016-10-17 |
| Results First Posted: | 2018-07-24 |
| Last Update Posted: | 2018-09-12 |
| Locations: | Chagwon, Korea, Republic of|Daegu, Korea, Republic of|Daejeon, Korea, Republic of|Gwangju, Korea, Republic of|Gyeonggi-do, Korea, Republic of|Jeonju, Korea, Republic of|Seoul, Korea, Republic of|Ulsan, Korea, Republic of|Wonju, Korea, Republic of |
| URL: | https://clinicaltrials.gov/show/NCT01972724 |
